In a phase I, two-part study of talazoparib in treatment refractory tumors, including germline BRCA1/2 mutant and other selected sporadic cancers, single agent antitumor activity was observed in BRCA1/2 mutation-associated breast and ovarian cancers, and also patients with pancreatic and small cell lung cancers whose tumors harbor genomic aberrations involving DNA repair mechanisms such as PALB2 mutations [31]. This evidence concerns the gene BRCA1 and ovarian carcinoma.